|
- Fierce Pharma Biopharma News Insights
Fierce Pharma delivers breaking news and analysis about drug companies, the FDA and the broader pharma industry, including manufacturing, marketing and finance
- Trumps pharmaceutical tariffs materialize at last in new US-EU trade . . .
At long last, the Trump administration’s much-ballyhooed tariffs on pharmaceutical imports are materializing in a trade deal with the European Union
- Manufacturing - Fierce Pharma
Connect The Team Advertise Marketing Kit Let's Talk Join Us Newsletters Resources RSS Feeds Our Brands Fierce Biotech Fierce Healthcare Fierce Pharma Our Events Life Sciences Events
- UK pharma drug price talks break down as industry fails to lower . . .
While the terms of the current VPAG period were reached in 2023, rising health demands and the introduction of newer drugs have put more pressure on the pharma industry to swallow the extra cost
- Trump admin rolls out EU trade deal with 15% pharma tariff rate
The terms of the deal likely provide some relief for the EU’s pharmaceutical industry, which now appears to be immune to higher sectoral tariffs that the Trump administration aims to impose on
- Drugmakers, trade groups and others hit back on tariff threat
Governments, trade groups and drugmakers have struck back against potential pharma tariffs in comments on a U S import investigation
- Of 22 top drugmakers, 21 showed revenue increases in Q4
Revenues in the biopharma industry continued to boom in the fourth quarter of last year Of 22 top companies, only one had a year-over-year decline
- 2024 approvals: Biopharma delivered 55 new drugs, biologics
Company: Servier Pharmaceuticals The scoop: With the approval of Voranigo, Servier has delivered the first major treatment advance in low-grade brain cancer in more than two decades
|
|
|